| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Co-Diagnostics shares are trading higher Monday after the company signed a definitive agreement to establish CoMira Diagnostics.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001692415/000149315225018591/form8-k.htm
D. Boral Capital analyst Jason Kolbert maintains Co-Diagnostics (NASDAQ:CODX) with a Buy and maintains $3 price target.